Author of

• 17629

  +

  P2.03b - Poster Session with Presenters Present (ID 465)

  • Event: WCLC 2016
  • Type: Poster Presenters Present
  • Track: Advanced NSCLC
  • Presentations: 1
  • Moderators:
  • Coordinates: 12/06/2016, 14:30 - 15:45, Hall B (Poster Area)

  • 17690

    +

    P2.03b-061 - Baseline Neutrophil–Lymphocyte Ratio is Related to Baseline Presence of Brain Metastases and Subsequent Brain Metastases in Stage IV NSCLC (ID 4685)

    14:30 - 14:30  |  Author(s): H.W. Lee
    • Abstract

    Background:
    We examine the predictive value of neutrophil–lymphocyte ratio (NLR) by examining their association with baseline presence and subsequent development of brain metastases in patients with stage IV non-small-cell lung cancer (NSCLC).
    
    Methods:
    We examined the predictive value of NLR for brain metastasis in 263 stage IV NSCLC using the receiver operating characteristic (ROC) curve analysis for optimal cut-off value. Logistic regression models were used to determine the association of NLR with the baseline presence of brain metastases. For patients without brain metastases at diagnosis, a competing risk analysis was performed, calculating the probability of brain metastasis in the presence of the competing risk of mortality by other causes using Gray’s test.
    
    Results:
    The median follow-up time was 11 months (range: 1–95 months). Univariate analysis reveals that patients with high NLR(≥4.95) had significantly more brain metastases at diagnosis than those with low NLR (P = 0.038), multivariate analysis was not performed because there was no significant risk factor for predicting brain metastases at diagnosis, except NLR. In patients who did not have baseline brain metastasis, competing risks analysis reveals that patients with high NLR showed higher cumulative incidence of subsequent brain metastases, compared to those with patients with low NLR (P = 0.02). A high NLR was associated with the baseline presence or the subsequent development of brain metastases, particularly in the group with adenocarcinoma (P = 0.006 and P = 0.04, respectively). Furthermore, an increase in NLR during treatment was associated with subsequent brain metastases (P = 0.003)
    
    Conclusion:
    The NLR is a predictive factor for the baseline presence of brain metastases and subsequent brain metastases in stage IV NSCLC. The NLR can be used to identify a subgroup of adenocarcinoma who is at a high risk for brain metastasis, and who may benefit from prophylactic treatment.